Foresite Capital Fund IV, L.P. - Sep 30, 2025 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James B. Tananbaum
Security
Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol
LYEL
Shares outstanding
19.1M shares
Disclosed Ownership
1.45M shares
Ownership
7.6%
Form type
SCHEDULE 13G/A
Date filed
11/14/2025, 04:05 PM
Date of event
Sep 30, 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 4.2% 800K 800K 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 4.2% 800K 800K 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.5% 477K 477K 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.5% 477K 477K 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 0.9% 177K 177K 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 0.9% 177K 177K 0 /s/ James Tananbaum James Tananbaum, Managing Member
James B. Tananbaum 7.6% 1.45M 1.45M 0 /s/ James Tananbaum James Tananbaum